Ruibao Ren

Summary

Affiliation: Brandeis University
Country: USA

Publications

  1. ncbi request reprint Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, MS029, Brandeis University, 415 South Street, Waltham, Massachusetts 02454 9110, USA
    Nat Rev Cancer 5:172-83. 2005
  2. ncbi request reprint Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models
    Ruibao Ren
    Leuk Lymphoma 43:1549-61. 2002
  3. ncbi request reprint The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts 02454 9110, USA
    Oncogene 21:8629-42. 2002
  4. ncbi request reprint Modeling the dosage effect of oncogenes in leukemogenesis
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Curr Opin Hematol 11:25-34. 2004
  5. pmc Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
    Chaitali Parikh
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454, USA
    Cancer Res 67:7139-46. 2007
  6. doi request reprint Mouse model for NRAS-induced leukemogenesis
    Chaitali Parikh
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, USA
    Methods Enzymol 439:15-24. 2008
  7. pmc IRF-4 functions as a tumor suppressor in early B-cell development
    Jaime Acquaviva
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Blood 112:3798-806. 2008
  8. pmc Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis
    Seung Hee Jo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA, USA
    Blood 116:2759-67. 2010
  9. pmc IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner
    Seung Hee Jo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, Massachusetts 02454, USA
    J Biol Chem 287:1770-8. 2012
  10. pmc Palmitoylation of oncogenic NRAS is essential for leukemogenesis
    Benjamin Cuiffo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA, USA
    Blood 115:3598-605. 2010

Research Grants

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, MS029, Brandeis University, 415 South Street, Waltham, Massachusetts 02454 9110, USA
    Nat Rev Cancer 5:172-83. 2005
    ..What have clinical trials of imatinib and studies using mouse models for BCR-ABL leukaemogenesis taught us about the functions of BCR-ABL beyond its kinase activity, and how these functions contribute to CML pathogenesis?..
  2. ncbi request reprint Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models
    Ruibao Ren
    Leuk Lymphoma 43:1549-61. 2002
    ....
  3. ncbi request reprint The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts 02454 9110, USA
    Oncogene 21:8629-42. 2002
    ..The in vivo studies of leukemogenesis will help to advance mechanism-based therapies for CML, as well as to understand fundamental rules of leukemogenesis and hematopoiesis...
  4. ncbi request reprint Modeling the dosage effect of oncogenes in leukemogenesis
    Ruibao Ren
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Curr Opin Hematol 11:25-34. 2004
    ....
  5. pmc Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
    Chaitali Parikh
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454, USA
    Cancer Res 67:7139-46. 2007
    ..The models established here provide a system for further studying the molecular mechanisms in the pathogenesis of myeloid malignancies and for testing targeted therapies...
  6. doi request reprint Mouse model for NRAS-induced leukemogenesis
    Chaitali Parikh
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts, USA
    Methods Enzymol 439:15-24. 2008
    ..This model provides a system for further studying the molecular mechanisms in the pathogenesis of myeloid malignancies and for testing targeted therapies...
  7. pmc IRF-4 functions as a tumor suppressor in early B-cell development
    Jaime Acquaviva
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Blood 112:3798-806. 2008
    ..The context dependent roles of IRF-4 in oncogenesis should be an important consideration in developing cancer therapies targeting IRF-4...
  8. pmc Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis
    Seung Hee Jo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA, USA
    Blood 116:2759-67. 2010
    ..Combined losses of IRF-4 and IRF-8 therefore can cooperate in the development of both myeloid and lymphoid tumors...
  9. pmc IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner
    Seung Hee Jo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, Massachusetts 02454, USA
    J Biol Chem 287:1770-8. 2012
    ..However, IRF-4 tumor suppressor activity is lost in IRF association domain (IAD) deletion mutants. These results demonstrate that IRF-4 suppresses BCR/ABL transformation by a novel cytoplasmic function involving its IAD domain...
  10. pmc Palmitoylation of oncogenic NRAS is essential for leukemogenesis
    Benjamin Cuiffo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA, USA
    Blood 115:3598-605. 2010
    ....
  11. ncbi request reprint Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide
    David Shackelford
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, Massachusetts 02454 9110, USA
    Cancer Res 66:11360-9. 2006
    ..Our results suggest that ATO could be used as a part of targeted therapy for AME-, AML1/MDS1-, MDS1/EVI1-, and EVI1-positive human cancers...
  12. pmc Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis
    Karina J Baum
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454, USA
    J Hematol Oncol 1:5. 2008
    ..These results suggest that Ras activation is essential for the development of lymphoid and erythroid cells but not myeloid cells and that Ras is a critical target of BCR/ABL in the pathogenesis of CML, but not B-ALL...
  13. pmc Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice
    Chaitali Parikh
    Rosenstiel Basic Medical Sciences Research Center, MS029, Brandeis University, Waltham, MA 02454 9110, USA
    Blood 108:2349-57. 2006
    ..The mouse model for NRAS leukemogenesis established here provides a system for further studying the molecular mechanisms in the pathogenesis of myeloid malignancies and for testing relevant therapies...
  14. ncbi request reprint Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice
    Grace M Cuenco
    Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, Waltham, MA 02454 9110, USA
    Oncogene 23:569-79. 2004
    ..The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML...
  15. ncbi request reprint The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl
    Yiping He
    Department of Pathology and Laboratory Medicine, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, USA
    Blood 99:2957-68. 2002
    ..These results show that both the bcr coiled-coil domain and Tyr177 are required for MPD induction by bcr/abl and provide the basis for investigating downstream signaling pathways that lead to CML...
  16. ncbi request reprint c-CBL is not required for leukemia induction by Bcr-Abl in mice
    Daniela M Dinulescu
    Department of Cell and Developmental Biology, OR, USA
    Oncogene 22:8852-60. 2003
    ..Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemogenesis in mice...
  17. ncbi request reprint Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development
    Jason A Wertheim
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, 611 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104 6160
    Blood 102:2220-8. 2003
    ..Together, our results suggest that F-actin localization may play a pivotal role in modulating adhesion but that it is dispensable for the development of CML...

Research Grants17

  1. Ras signaling in leukemogenesis
    Ruibao Ren; Fiscal Year: 2010
    ..The ultimate goal of these studies is to identify critical molecular events in Ras leukemogenesis, allowing therapeutic interventions of leukemias involving Ras. ..
  2. IDENTIFICATION OF TARGETS OF BCR ABL IN THE LEUKEMOGENIC
    Ruibao Ren; Fiscal Year: 2005
    ..These studies will help to further design rational therapeutic interventions for CML and to understand the mechanisms involved in leukemogenesis in general. ..
  3. REGULATION OF IMMUNOGLOBULIN GENE EXPRESSION IN B CELLS
    Ruibao Ren; Fiscal Year: 2003
    ..The rules of combinatorial transcription activation will also allow the design of novel transcription regulatory sequences to direct therapeutic expression of exogenous genes in selected cells. ..
  4. BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC PATHWA
    Ruibao Ren; Fiscal Year: 2000
    ....
  5. Ras signaling in leukemogenesis
    Ruibao Ren; Fiscal Year: 2009
    ..The ultimate goal of these studies is to identify critical molecular events in Ras leukemogenesis, allowing therapeutic interventions of leukemias involving Ras. ..